BioSpace News Archive

Gossamer Bio, Inc. announced its financial results for the quarter ended March 31, 2019 and provided a corporate update.

Avivagen Inc. announces the appointments of Mr. Kym Anthony to the position of C.E.O. and Mr. Jeffrey Kraws, a director of the Corporation, to the position of Chairman of the Board.

Mallinckrodt’s CONFIRM study is evaluating the efficacy and safety of terlipressin in hepatorenal syndrome type 1

Soligenix, Inc. announced its recent accomplishments and financial results for the quarter ended March 31, 2019.

Protagonist Therapeutics, Inc. announced results from the initial single ascending dose (SAD) part of the Phase 1 study of PN-943, an oral, gut-restricted alpha-4-beta-7 integrin specific antagonist in development for the potential treatment of inflammatory bowel disease (IBD).

Elixir Medical Corporation announced that it will release at EuroPCR in Paris 9 and 12-month clinical and imaging data for the DynamX™ Novolimus-eluting Bioadaptor System, a next-generation coronary intervention system designed to treat blocked arteries via a novel “uncaging” mechanism.

The 9th Annual Medical Device & Diagnostic Labeling Conference gathers thought leaders, regulators and solution providers to explore timely topics related to packaging and labeling strategies, new regulations, in-country review processes and content development and management, through engaging formats at this annual industry-recognized networking event.

Survivorship Today Aims to Shed Light on the Long-Term Impacts of Living with Cancer

Haemonetics Corporation and CSL Plasma Inc. announced an agreement to transfer ownership of Haemonetics’ Union, South Carolina, manufacturing facility, operating assets and certain inventories to CSL Plasma.

New survey shows more can be done to protect those with a chronic condition